ZM001 injection for hard-to-treat lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests an experimental injection called ZM001 for people with refractory systemic lupus erythematosus (SLE) who haven't gotten better after standard treatments. It aims to see if ZM001 can help control moderate to severe disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a confirmed diagnosis of lupus (SLE) with moderate to severe disease activity.
- Have tried and not responded well to at least one biologic therapy (like belimumab or rituximab) along with steroids and other immune-suppressing drugs.
- Be between 18 and 70 years old.
- Have adequate organ function, including blood counts, kidney function, and heart function.
- Not have certain other medical conditions, such as active infections, recent cancer, or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection (CM313) to see if it can help people with active lupus. It's for those whose lupus symptoms aren't fully controlled despite standard treatments.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This trial tests an investigational drug called QLS4131 in people with active systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding QLS4131 can help control lupus activity better.
This study tests an investigational drug called ACG102, given as an injection, for people with active lupus that hasn't improved with standard treatments. The goal is to see if it can help control the disease and reduce symptoms.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.